Trials / Completed
CompletedNCT00998699
Study of the Effects of XOMA 052 on Insulin Production in Subjects With Well Controlled Type 1 Diabetes
A Randomized, Double-blind, Placebo-controlled, Phase 2 Study of the Effects of XOMA 052 on Insulin Production in Subjects With Well-controlled Type 1 Diabetes
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 22 (actual)
- Sponsor
- XOMA (US) LLC · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Not accepted
Summary
The study hypothesis is that XOMA 052 may inhibit beta-cell destruction and enhance beta-cell regeneration. The purpose of this study is to assess the effects of XOMA 052 on beta-cell function and insulin production.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Xoma 052 | Sterile solution subcutaneously administered every 4 weeks for 12 weeks |
| DRUG | Placebo | Sterile solution subcutaneously administered every 4 weeks for 12 weeks |
Timeline
- Start date
- 2010-02-01
- Primary completion
- 2013-08-01
- Completion
- 2013-08-01
- First posted
- 2009-10-20
- Last updated
- 2014-03-04
Locations
2 sites across 1 country: Switzerland
Source: ClinicalTrials.gov record NCT00998699. Inclusion in this directory is not an endorsement.